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Abstract. The study of dendritic cells (DCs) 
has seen a rapid expansion in recent years, and their 
importance within the immune system is now widely 
recognized. Along with B lymphocytes and mononu­
clear phagocytes, DCs make up what are known as 
the professional antigen-presenting cells (APCs). 
These are cells which are capable of highly efficiently 
presenting antigens to the immune system in the con­
text of both major histocompatibility complex class I 
and class II molecules. What makes DCs stand out 
from other professional APCs, however, is their 
seemingly unique ability to present antigen to T lym­
phocytes which have had no previous contact with 
antigen. This gives DCs a central role in the initiation 
of immune responses, and creates possibilities for 
their exploitation in the development of therapeutic 
strategies against tumors and other diseases.
What are the characteristics of DCs which 
enable them to carry out their specialized func­
tion? This is a question which is currently gaining 
much interest. While higher expression levels of 
the antigen-presentation machinery may account 
for this, there may also be as yet unidentified 
mechanisms at work. In this review, we will dis­
cuss the evidence for DC-mediated priming of 
both CD4+ and CD8+ naive T cells, both in vitro 
and in vivo, current ideas on how DCs achieve 
their potent function and the implications for the 
design and execution of immunotherapeutic  
strategies. Stem Cells 1996;14:501-507
Introduction
Dendritic cells (DCs) are a diverse system 
of cells which have been identified in all tis­
sues of the body, with the exception of the brain. 
First described less than 25 years ago [1], their
Correspondence: Dr. Gill Marland, Department 
of Tumor Immunology, University Hospital 
Nijmegen, Philips van Leydenlaan 25, 6525 EX 
Nijmegen, The Netherlands.
Accepted for publication May 23, 1996. 
©AlphaMed Press 1066-5099/96/$5.00/0
STEM CELLS 1996;14:501-50J 0 ^
Downloaded from www.StemG
study has been hampered by two main factors. 
First, they are present in the blood and tissues in 
very low amounts. Among peripheral blood 
mononuclear cells (PBMCs) they account for 
less than 1%. Second, there are as yet no known 
DC-specific cell surface antigens with which 
to aid their positive identification, Despite these 
difficulties, significant progress is being made 
towards an understanding of DCs, particularly 
with respect to their role in antitumor immu­
nity, allograft rejection and the pathogenesis of  
AIDS. The lineage relationship of DCs to other 
leukocytes is not completely understood, and 
even within the DC system there is consider­
able heterogeneity. They remain, therefore, most 
readily defined in terms of their function, 
notably their strong accessory function for the 
stimulation of T cells.
Ontogeny of DCs
DCs originate from hematopoietic stem 
cells, although their stages of differentiation 
from progenitors are poorly understood. A 
myeloid origin has been proposed for these cells, 
based on their shared responsiveness to GM-CSF 
with monocytes and granulocytes. A common 
progenitor has been identified in cultures o f  
major histocompatibility complex (MHC) class 
II negative mouse bone marrow cells which, in 
the presence of GM-CSF, proliferate and dif­
ferentiate into mixed colonies containing DCs, 
monocytes and granulocytes [2]. Furthermore, 
a progenitor has been identified in human bone 
marrow which can give rise to both DCs and 
monocytes, indicating that DCs may branch from 
the mononuclear phagocyte lineage [3].
Following their departure from the bone 
marrow, DCs enter the blood and migrate to the 
tissues. The best characterized tissue DC is the 
Langerhans cell (LC) of the skin. LCs express Fc
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receptors (FcRs) which enable these cells to take 
up antigen specifically. On culturing both human 
and mouse LCs, however, FcR expression is lost 
while the expression of MHC class I and II is 
increased [4, 5]. As demonstrated in the murine 
system [4], this correlates with a 10-fold increase 
in activity in the mixed leukocyte reaction 
(MLR), which is indicative of their T cell stim­
ulatory capacity. Based on these findings, a 
model delineating two main stages of DC matu­
ration has been proposed. First, immature DCs 
are capable of taking up and processing antigen, 
and second, mature DCs are efficient at pre­
senting antigen to T cells. In vivo tissue-resi­
dent DCs, such as LCs, could be classed as 
immature DCs. Following antigen uptake, these 
cells are mobilized and migrate via the afferent 
lymph and blood to secondary lymphoid organs 
where they stimulate T cell responses. The mobi­
lization of these DCs is concomitant with their 
differentiation into mature DCs.
Isolation and In Vitro Generation of DCs
Conventional methods for the isolation of 
DCs from PBMCs involve the successive deple­
tion of populations of non-DCs [6]. T cells are 
removed by rosetting with neuraminidase-treated 
sheep red blood cells, and monocytes by their 
adhesive properties or by panning with antibod­
ies that bind to FcRs. B cells and natural killer 
cells are removed following centrifugation over 
metrizamide gradients, yielding a low-density 
fraction which is highly enriched for DCs. As an 
additional step, DCs can be further purified by 
selecting for cells which do not express known 
lineage markers such as CD3, CD 19, CD56 and 
CD 14. While a reasonably pure population of 
DCs can be obtained, these methods are 
time-consuming and often result in low yields 
of cells with an unknown activation status.
In order to circumvent the difficulties 
encountered during the isolation of peripheral 
blood DCs, methods have been developed for 
the generation o f DCs in vitro. Starting with 
either bone marrow or blood cells, murine DCs 
were generated following culture in the presence 
of GM-CSF [7, 8]. GM-CSF could similarly be 
used in the generation o f human DCs, but 
required in addition tumor necrosis factor a  
(TNF-a) when starting with CD34+ progenitor 
cells [9], and interleukin 4 (IL-4) when starting
with peripheral blood [10, 11], From peripheral 
blood it has been found that GM-CSF in combi­
nation with IL-4 results in a yield of DCs which 
is 40- to 80-fold higher than would normally be 
expected from peripheral blood [10,11]. While a 
small proportion of these cells may arise from 
proiiferatingprogenitors present in the blood, it 
is likely that the majority are derived from mono­
cytes. The relationship between DCs freshly iso­
lated from peripheral blood to those generated 
in vitro, either from hematopoietic progenitors 
or peripheral blood, remains to be established.
DC Phenotype
DCs share many features with mononu­
clear phagocytes, although there are also clear 
differences which allow for the identification 
of DCs by phenotypic and morphological cri­
teria (Table 1). DCs are large cells with oval 
or irregularly shaped nuclei and a cytoplasm 
possessing few organelles. A characteristic 
of DCs is their constant formation and retrac­
tion of cytoplasmic processes or veils. The 
heterogeneity of DCs is reflected in the anti­
genic profiles o f the cells isolated from dif­
ferent sources and using different isolation 
procedures. However, consistent with their 
role as antigen-presenting cells (APCs), DCs 
express high levels o f MHC class I and class
Table I. Morphological, phenotypic and functional 
characteristics of mature DCs
Morphology
Oval or irregularly shaped nuclei 
Few cytoplasmic organelles 
Constant formation and retraction of cytoplasmic 
processes
Phenotype
High expression of MHC class I and class II 
High expression of costimulatory molecules 
Little or no expression of FcR 
Expression of CD la 
Expression of CD83 (human)
Expression of DEC-205 (mouse)
Function
Weakly phagocytic 
Potent stimulators of an MLR
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II m olecules, as well as the costimulatory
m olecules CD80 (B7-1) and CD86 (B7-2), 
and adhesion m olecu les such as LFA -1, 
LFA-3 and ICAM-1, They are negative for 
lineage markers such as CD3, CD14, CD19, 
CD20 and CD56.
While efforts have been made to identify 
antigens which are specific for DCs, no markers 
are yet known. There are antigens, however, 
which have a restricted expression and are used in 
the positive identification of DCs, most notably 
CD la, which is also present on thymocytes. CD la 
is expressed on LCs and DCs and is often used 
to distinguish them from monocytes. CD83, a 
member of the immunoglobulin superfamily 
whose function is unknown, appears to be 
DC-specific among peripheral blood cells, and 
furthermore, is associated with mature DCs [12]* 
The leukocyte integrin CD1 lc  (p i50,95) is pre­
sent at high levels on DCs and in the mouse is 
relatively DC-specific. Another molecule asso­
ciated with murine DCs is the molecule DEC-205
[13], which may play a role in antigen uptake and 
will be discussed later.
As mentioned previously, the addition of 
TNF-oc to CD34* cells is thought to provide an 
early signal in the induction o f  DCs. This 
cytokine has a strikingly different effect, how­
ever, on DCs generated by GM-CSF and IL-4 
stimulation of PBMCs. When these DCs are fur­
ther stimulated for 24 h with TNF-a, they exhibit 
an increased T cell stimulatory capacity in an
MLR and a 10-fold decrease in presentation o f  
soluble tetanus toxoid to specific T cell clones 
[10]. These findings suggest that incubation o f  
PBMCs with GM-CSF and IL-4 gives rise to 
immature DCs which are capable of antigen 
uptake and processing, while further incubation 
with TNF-a induces their maturation into cells 
capable of antigen presentation.
As shown in Figure 1, the maturational 
changes in DCs are associated with changes in 
expression levels o f the surface antigens 
involved in DC function. Immature DCs, there­
fore, express higher levels o f the molecules 
involved in antigen uptake, such as FcRs and 
the mannose receptor. Maturation is accompa­
nied by a decrease or loss o f such molecules, 
and an increase in the expression levels o f MHC 
class I and II and costimulatory molecules.
Primary Immune Response Induction
The hallmark of DCs is their ability to prime 
naive T lymphocytes of both the CD4+ and CD8+ 
phenotypes. Often their stimulatory capacity has 
been studied using the MLR, which is the most 
powerful primary T cell response analyzed in 
culture. In this system, the immune response is 
monitored by measuring DNA synthesis or 
cytolytic T cell activity after four to six days’ 
culture in vitro. The results of such studies indi­
cate that DCs are approximately 100 times as
Immature DC
antigen uptake and
processing
mannose
nxcptor
othermokcultt ?
maturation
migration
Mature DC
antigen presentation
cwilmutoUwy
mokcufei MHC cUu l/tt
Tissues Blood/Lymph Lymphoid organs
Figure L The two main functional stages o f  DC maturation. The cell surface molecules which play an important 
role in the two stages are indicated.
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efficient as monocytes or lymphocytes in driv­
ing the proliferation of allogeneic lymphocytes, 
and are the only cell type able to induce responses 
using autologous responder lymphocytes [6].
The efficiency with which DCs prime naive 
T cells has been attributed to high expression 
levels of MHC class I, class II and costimula­
tory molecules, retention of antigen for rela­
tively long periods o f time [14], and decreased 
sialylation o f MHC molecules [15]. A feature 
of DCs that may explain their stimulatory capac­
ity is their ability to form large clusters with 
lymphocytes, a phenomenon that does not occur 
using other types o f APC [16]. Certainly, their 
irregular shape and ability to form long cyto­
plasmic processes make each DC well-disposed 
to make contact with multiple T cells. While a 
combination o f these characteristics may be 
responsible for their enhanced APC capacity, 
there may well be further, as yet unidentified, 
mechanisms at work.
MHC Class I-Dependent Responses
+
As well as being strong stimulators in an 
MLR, DCs have been shown to be potent induc­
ers o f antigen-specific primary immune 
responses. When pulsed with MHC class 
I-restricted viral peptides, DCs were able to 
induce strong cytotoxic T lymphocyte (CTL) 
responses against infected or pep tide-pul sed tar­
gets [17-20]. In DC-mediated induction of these 
antiviral responses, proliferation of antigen-spe­
cific CD4* T cells significantly augmented the 
development o f CTL responses [17, 18, 21]. 
However the CD4+ T cells could be replaced by 
cytokines derived from these cells, indicating 
that the presence of the cells themselves was not 
an absolute requirement [22].
In vitro induction of virus-specific primary 
CTL responses was shown using DCs as APCs 
that were either infected with virus or exoge­
nously loaded with MHC class I-binding syn­
thetic peptides. DCs pulsed with total viral antigen 
were a poor stimulus for the development of CTLs 
[17], while pulsing with a noninfectious virus led 
only to a CD4+ T cell response [18]. This sug­
gests that DCs have no efficient mechanism for 
the uptake and delivery of exogenous antigen into 
the MHC class I processing pathway. However, it 
is also possible that this phenomenon does occur 
in DCs but is tightly regulated and restricted to
a certain stage of maturation. Alternative strate­
gies for the incorporation of exogenous antigen 
into the class I pathway of DCs have included 
direct antigen delivery into the cytoplasm via 
osmotic lysis of pinocytotic vesicles or via uptake 
of pH-sensitive liposomes. Using these methods, 
primary CTLs have been induced both in vivo, 
in a murine model system using ovalbumin as 
antigen, and in vitro, using keyhole limpet hemo- 
cyanin as antigen [22,23]. Alternatively, de novo 
synthesis of the desired antigens by DCs could 
be accomplished via transfection or viral trans­
duction of antigen-encoding DNA, thus leading to 
MHC class I presentation [24].
MHC Class II-Dependent Responses
Studies in the mouse have shown that spleen 
DCs pulsed with antigen in vitro and adminis­
tered to naive mice were capable of priming T 
cells [25]. When used in the same system, how­
ever, B cells and macrophages were largely inef­
fective. Restimulation of the T cells in vitro was 
found to be class II-dependent and the resulting 
antigen-reactive T cells were predominantly 
CD4+. In a separate study, characterization of  
CD4+ T cells primed by peptide-loaded spleen 
DCs in vitro showed that, in the presence of IL-4- 
blocking antibodies, DCs could drive the 
response toward cells of the Thl phenotype [26]. 
Thl cells, characterized by their secretion of 
interferon y (IFN-y), are involved in the genera­
tion of CD8+ T cell responses, while Th2 cells, 
which produce IL-4, provide help in humoral 
immune responses. The ability of DCs to aug­
ment a Thl response was attributed to the pro­
duction by the DCs of IL-12, a known director of 
Thl responses [27].
In vitro studies have shown that human 
peripheral blood DCs are capable of stimulat­
ing previously unsensitized CD4+ T cells  
against a panel of antigens [28]. Antigen-spe- 
cifíc T cell activation was dependent upon the 
presence in the starting population o f  
CD45RA* cells, indicative o f naive T cells, 
and they retained their antigen specificity after 
long periods in culture. While DCs were an 
absolute requirement for the initial sensitiza­
tion, restimulation of these T cell lines could be 
achieved using macrophages as APCs instead 
of DCs. This observation gives credence to the 
idea that the specialized function of DCs is to
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sensitize naive T cells which are then able to 
interact with other APCs.
While the supremacy o f  DCs over other 
APCs in the priming of CD4+ T cells is undis­
puted, the mechanisms by which they take up 
antigen are less clear. When compared to 
macrophages, DCs are weakly endocytic and do 
not express the same array of FcRs. However, it 
has been suggested that DCs use macropinocyto- 
sis rather than endocytosis to concentrate antigen 
intracellularly [29]. Unlike other cell types, DCs 
appear to be constitutively active for macropinocy- 
tosis, thus allowing for the continuous uptake of 
large volumes of fluid. It is also possible that DCs 
express some as yet uncharacterized antigen-spe­
cific receptors. One candidate which has been pro­
posed is the mannose receptor, which is expressed 
on in vitro-generated DCs. This molecule has pre­
viously been associated with the scavenging capac­
ity o f macrophages, but could provide some 
selectivity for foreign antigens due to its ability 
to bind glycoproteins expressed predominantly 
on pathogens [29]. Similarly, the murine mole­
cule DEC-205, which is homologous to the man­
nose receptor, has been associated with antigen 
uptake [13]. It was observed that rabbit antibodies 
against DEC-205 were presented 100 times
more efficiently to rabbit Ig-specific T cell 
hybridomas than were rabbit antibodies against 
irrelevant antigens.
DCs as Inducers of Antitumor Immune 
Responses
Immunosurveillance of tumor cells by the 
cellular immune system is often inefficient in 
vivo, which is reflected in the outgrowth of 
tumors that are apparently unable to evoke an 
immune response. An explanation often presented 
is that the tumor cells are unable to prime anti­
tumor T cells, which could be due to a number 
of reasons. First, it may reflect an inability of the 
tumor cells to provide the necessary costimula­
tory signals for T cell activation. Second, the 
tumor cells may not express sufficient antigenic 
determinants that can be seen by the immune sys­
tem. Third, it could be that the tumor cells secrete 
inhibitory factors such as transforming growth 
factor ß (TGF-ß) or IL-10 which have a suppres­
sive effect on local APCs. Since DCs have been 
shown to be potent inducers of antiviral CTL 
responses, they may also be instrumental in the
induction of T cell-mediated antitumor responses. 
A suggestion supporting this comes from the clin­
ical observation that infiltration of presumptive 
DCs into tumor tissue seems to correlate with a 
favorable clinical prognosis [30].
Several groups have reported the induc­
tion o f MHC class II-m ediated immune 
responses after stimulation with tumor anti­
gen-pulsed DCs in vitro and in vivo [25, 
31-33], In addition, DCs pulsed with tumor 
antigen in vitro have been shown to induce 
tumor resistance in vivo [34-36]. Recently, it 
was demonstrated that intravenous injection 
o f  DCs pulsed in vitro with a single MHC 
class I-restricted CTL epitope induced a pro­
tective CTL response in v ivo, capable o f  
resisting a subsequent challenge with tumor 
cells expressing the relevant epitope [37]. 
Moreover, eradication of established tumors 
was achieved using peptide-loaded DCs in the 
same and two other murine tumor models [38], 
Interestingly, in this report therapeutic effects 
were observed when DCs were pulsed with 
tumor-derived crude peptide extracts rather 
than with synthetic peptide. This could  
broaden the applicability o f peptide-pulsed 
DCs as the need for defining immunogenic 
peptides is abrogated. In addition, there may 
be an enhancing effect on CTL generation due 
to the inclusion of additional class II-restricted 
epitopes for the stimulation of CD4+ T cells.
Based on the data obtained from murine mod­
els, it is tempting to speculate that administration 
of DCs may also be effective in generating cellu­
lar immunity to tumors in patients. In testing the 
validity of such a hypothesis, most studies have 
been performed on melanoma, as the immuno­
genic properties of antigens associated with this 
tumor have been well-defined. Recently, it was 
reported that upon injection of dendritic-like cells 
loaded with a melanoma CTL epitope into 
melanoma patients, tumor-specific CTL could be 
isolated from the vaccination site and adjacent 
tumor tissue [39]. This indicates that, indeed, pep­
tide-specific CTLs have been induced by DCs in 
vivo. Furthermore, vaccination of patients with B 
cell lymphoma using autologous antigen-pulsed 
DCs resulted in measurable antibody responses 
in four out of four patients treated [40], In addition, 
clinical responses, including one complete 
response, were observed in this study.
Until recently, the use of DCs as immunother- 
apeutic agents has been hampered by their low
Downloaded from www.StemCells.com by on July 26, 2006
506 Dendritic Cells in Immune Response Induction
frequency and difficulties in their isolation, as dis­
cussed earlier in this review. However, with the 
development of methods for the generation of DCs 
in vitro, sizeable numbers of DCs are now avail­
able and have already become valuable tools in 
the elucidation of antitumor responses. We have 
shown that using such DCs, CTL responses against 
melanoma-associated antigen-derived epitopes 
can be elicited in vitro, from healthy donor-derived 
peripheral blood lymphocytes [41], The next step 
would be to generate large amounts of DCs in 
vitro, expose them to antigen and reinfuse them 
into patients. A lthough this prom ising  
im m unotherapeutic concept may at the 
moment be only applicable using broadly 
expressed antigens in melanoma, a similar 
approach may be applicable to other solid tumors.
Concluding Remarks
The applicability o f DCs in the generation 
of both MHC class I- and class II-restricted pri­
mary T cell responses against a variety of anti­
gens has been demonstrated. However, there are 
many questions which remain to be answered 
regarding the function of DCs. In particular, it is 
still unclear as to what the specific characteris­
tics are which make DCs so different from other 
professional APCs. While the search for these 
answers continues, the exploitation of DCs in the 
clinical setting is already progressing. Especially 
promising is their usefulness in the generation of 
tumor vaccines, a field which will no doubt show 
rapid developments in the near future.
Acknowledgments
Supported by grants ERBCHBICT 930835 
from the European Community, and KUN 91245 
and KUN 91246 from the Dutch Cancer Society.
References
1 Steinman RM, Cohn ZA. Identification of a novel 
cell type in peripheral lymphoid organs of mice. I. 
Morphology, quantitation, tissue distribution. J Exp 
Med 1973;137:1142-1162.
2 Inaba K, Inaba M, Deguchi M et al. 
Granulocytes, macrophages, and dendritic cells 
arise from a common major histocompatibility 
complex class Il-negative progenitor in mouse
bone marrow. Proc Natl Acad Sci USA 
1993;90:3038-3042.
3 Reid CD, Fryer PR, Clifford C et al. Identification 
of hematopoietic progenitors of macrophages and 
dendritic Langerhans cells (DL-CFU) in human 
bone marrow and peripheral blood. Blood 
1990;76:1139-1149.
4 Schuler G, Steinman RM. Murine epidermal 
Langerhans cells mature into potent immuno- 
stimulatory dendritic cells in vitro. J Exp Med 
1985;161:526-546.
5 Romani N, Lenz A, Glassei H et al. Cultured 
human Langerhans ceils resemble lymphoid den­
dritic cells in phenotype and function. J Invest
Dermatol 1989;93:600-609.
6 Freudenthal PS, Steinman RM. The distinct sur­
face of human blood dendritic cells, as observed 
after an improved isolation method. Proc Natl 
Acad Sci USA 1990;87:7698-7702.
7 Inaba K, Steinman RM, Pack MW et al. 
Identification of proliferating dendritic cell pre­
cursors in mouse blood. J Exp Med 
1992;175:1157-1167.
8 Inaba K, Inaba M, Romani N et al. Generation 
of large numbers of dendritic cells from mouse 
bone marrow cultures supplemented with granu­
locyte/macrophage colony-stimulating factor. 
J Exp Med 1992;176:1693-1702.
9 Caux C, Dezutter Dambuyant C, Schmitt D et al. 
GM-CSF and TNF-alpha cooperate in the gen­
eration of dendritic Langerhans cells. Nature 
1992;360:258-261.
10 Sallusto F, Lanzavecchia A, Efficient presentation 
of soluble antigen by cultured human dendritic 
cells is maintained by granulocyte/macrophage 
colony-stimulating factor plus interleukin 4 and 
downregulated by tumor necrosis factor alpha. J
Exp Med 1994;179:1109-1118.
11 Romani N, Gruner S, Brang D et al. Proliferating 
dendritic cell progenitors in human blood. J Exp 
Med 1994;180:83-93.
12 Zhou LJ, Tedder TF. Human blood dendritic 
cells selectively express CD83, a member of 
the immunoglobulin superfamily. J Immunol 
1995;154:3821-3835.
13 Jiang W, Swiggard WJ, Heufler C et al. The 
receptor DEC-205 expressed by dendritic cells 
and thymic epithelial cells is involved in antigen 
processing. Nature 1995;375:151-155.
14 Bhardwaj N, Young JW, Ni sani an AJ et al. Small 
amounts of superantigen, when presented on den­
dritic cells, are sufficient to initiate T cell 
responses. J Exp Med 1993;178:633-642.
15 Neefjes JJ, De Bruijn ML, Boog CJ et al. N-linked 
glycan modification on antigen-presenting cells
Downloaded from www.StemCells.com by on July 26, 2006
Marland, Bakker, Adema et al. 507
restores an allospecific cytotoxic T cell response. 
J Exp Med 1990;171:583-588.
16 Flechner ER, Freudenthal PS, Kaplan G et al. 
Antigen-specific T lymphocytes efficiently clus­
ter with dendritic cells in the human primary 
mixed-leukocyte reaction. Cell Immunol
1988;111:183-195.
17 Macatonia SE, Patterson S, Knight SC. Primary 
proliferative and cytotoxic T-cell responses to 
HIV induced in vitro by human dendritic cells. 
Immunol 1991;74:399-406.
18 Nonacs R, Humborg C, Tam JP et al. Mechanisms of 
mouse spleen dendritic cell function in the generation 
of influenza-specific, cytolytic T lymphocytes. J Exp 
Med 1992;176:519-529.
19 Takahashi H, Nakagawa Y, Yokomuro K et al. 
Induction of CD8+ cytotoxic T lymphocytes by 
immunization with syngeneic irradiated HIV-1 
envelope derived peptide-pulsed dendritic cells. 
Int Immunol 1993;5:849-857.
20 De Bruijn ML, Nieland JD, Schumacher TN et 
al. Mechanisms of induction of primary virus-spe­
cific cytotoxic T lymphocyte responses. Eur J 
Immunol 1992;22:3013-3020.
21 Macatonia SE, Taylor PM, Knight SC et al. 
Primary stimulation by dendritic cells induces 
antiviral proliferative and cytotoxic T cell responses 
in vitro. J Exp Med 1989;169:1255-1264.
22 Mehta-Damani A, Markowicz S, Engleman EG. 
Generation of antigen-specific CD8+ CTLs from 
naive precursors. J Immunol 1994;153:996-1003.
23 Okada CY, Rechsteiner M. Introduction of 
macromolecules into cultured mammalian cells 
by osmotic lysis of pinocytic vesicles. Cell 
1982;29:33-41.
24 Alijagic S, Moller P, Artuc M et al. Dendritic 
cells generated from peripheral blood transfected 
with human tyrosinase induce specific T cell acti­
vation. Eur J Immunol 1995;25:3100-3107,
25 Inaba K, Metlay JP, Crowley MT et al. Dendritic 
cells pulsed with protein antigens in vitro can 
prime antigen-specific, MHC-restricted T cells 
in situ. J Exp Med 1990;172:631-640.
26 Macatonia SE, Hosken NA, Litton M et al. 
Dendritic cells produce IL-12 and direct the 
development of Thl cells from naive CD4+ T 
cells. J Immunol 1995;154:5071-5079.
27 Hsieh CS, Macatonia SE, Tripp CS et al. 
Development of Thl CD4+ T cells through IL-12 
produced by Listeria-induced macrophages. 
Science 1993;260:547-549.
28 Mehta-Damani A, Markowicz S, Engleman EG. 
Generation of antigen-specific CD4+ T cell lines 
from naive precursors. Eur J Immunol 
1995;25:1206-1211.
29 Sallusto F, Cella M, Danieli C et al. Dendritic 
cells use macropinocytosis and the mannose 
receptor to concentrate macromolecules in the 
major histocompatibility complex class II com­
partment: downregulation by cytokines and bac­
terial products. J Exp Med 1995;182:389-400.
30 Becker Y. Anticancer role of dendritic cells 
(DCs) in human and experimental cancers - a 
review. Anticancer Res 1992; 12:511-520.
31 Cohen PJ, Cohen PA, Rosenberg SA et al. Murine 
epidermal Langerhans cells and splenic dendritic 
cells present tumor-associated antigens to primed 
T cells. Eur J Immunol 1994;24:315-319.
32 Sornasse T, Flamand V, De Becker G et al. 
Antigen-pulsed dendritic cells can efficiently 
induce an antibody response in vivo. J Exp Med 
1992;175:15-21.
33 Cohen PA, Cohen PJ, Rosenberg SA et al. CD4+ 
T-cells from mice immunized to syngeneic sarco­
mas recognize distinct, non-shared tumor antigens. 
Cancer Res 1994;54:1055-1058.
34 Flamand V, Sornasse T, Thielemans K et al. 
Murine dendritic cells pulsed in vitro with tumor 
antigen induce tumor resistance in vivo. Eur J 
Immunol 1994;24:605-610.
35 Knight SC, Hunt R, Dore C et al. Influence of 
dendritic cells on tumor growth. Proc Natl Acad 
Sci USA 1985;82:4495-4497.
36 Gyure LA, Barfoot R, Denham S et al. Immunity 
to a syngeneic sarcoma induced in rats by den­
dritic lymph cells exposed to the tumour either 
in vivo or in vitro. Br J Cancer 1987;55:17-20.
37 Ossevoort MA, Feltkamp MC, van Veen KJ et 
al. Dendritic cells as carriers for a cytotoxic 
T-lymphocyte epitope-based peptide vaccine in 
protection against a human papillomavirus type 
16-induced tumor. J Immunother 1995;18:86-94.
38 Zitvogel L, Mayordomo II, Tjandrawan T et al. 
Therapy of murine tumors with tumor pep­
tide-pulsed dendritic cells: dependence on T cells, 
B7 costimulation, and T helper cell 1-associated 
cytokines. JExp Med 1996;183:87-97.
39 Mukherji B, Chakraborty NG, Yamasaki S et al. 
Induction of antigen-specific cytolytic T cells in 
situ in human melanoma by immunization with 
synthetic peptide-pulsed autologous antigen pre­
senting cells. Proc Natl Acad Sci USA 
1995;92:8078-8082.
40 Hsu FJ, Benike C, Fagnoni F et al. Vaccination of 
patients with B-cell lymphoma using autologous 
antigen-pulsed dendritic cells. Nat Med 
1996;2:52-58.
41 Bakker AB, Marland G, De Boer AJ et al. 
Generation of antimelanoma cytotoxic T lym­
phocytes from healthy donors after presentation 
of melanoma-associated anti gen-derived epitopes 
by dendritic cells in vitro. Cancer Res 
1995;55:5330-5334.
Downloaded from www.StemCells.com by on July 26, 2006
